These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25302034)

  • 21. Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada.
    Vanderpuye-Orgle J; Erim D; Qian Y; Boyne DJ; Cheung WY; Bebb G; Shah A; Pericleous L; Maruszczak M; Brenner DR
    Oncol Ther; 2022 Jun; 10(1):195-210. PubMed ID: 35230672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers.
    Srikanthan A; Penner N; Chan KKW; Sabharwal M; Grill A
    Curr Oncol; 2018 Aug; 25(4):257-261. PubMed ID: 30111966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Oncology Drug Review Times on Public Funding Recommendations.
    Hussain M; Wong C; Taguedong E; Verma S; Mahsin M; Karim S; Lee-Ying R; Ezeife DA
    Curr Oncol; 2023 Aug; 30(8):7706-7712. PubMed ID: 37623039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
    Lexchin J
    BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
    Parmar A; Jiao T; Saluja R; Chan KKW
    Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using a rapid environmental scan methodology to map country-level global health research expertise in Canada.
    Nagi R; Rogers Van Katwyk S; Hoffman SJ
    Health Res Policy Syst; 2020 Apr; 18(1):37. PubMed ID: 32272941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activities of the pan-Canadian Pharmaceutical Alliance: An Observational Analysis.
    Rocchi A; Mills F
    J Popul Ther Clin Pharmacol; 2018 Aug; 25(2):e12-e22. PubMed ID: 30725539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
    Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
    J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Research to Action: an evaluation.
    Murphy GT; Alder R; MacKenzie A; Cook A; Maddalena V
    Nurs Leadersh (Tor Ont); 2012 Mar; 25 Spec No 2012():21-32. PubMed ID: 22398474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canada's health system.
    Davies BJ
    Croat Med J; 1999 Jun; 40(2):280-6. PubMed ID: 10234072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canada's contribution to global research in cardiovascular diseases.
    Nguyen HV; de Oliveira C; Wijeysundera HC; Wong WW; Woo G; Grootendorst P; Liu PP; Krahn MD
    Can J Cardiol; 2013 Jun; 29(6):742-6. PubMed ID: 23219608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What does meaningful look like? A qualitative study of patient engagement at the Pan-Canadian Oncology Drug Review: perspectives of reviewers and payers.
    Rozmovits L; Mai H; Chambers A; Chan K
    J Health Serv Res Policy; 2018 Apr; 23(2):72-79. PubMed ID: 29624087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
    Lemieux J; Audet S
    Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An international perspective on Canada's role in cancer staging.
    Sobin LH
    Cancer Prev Control; 1998 Dec; 2(6):310-1. PubMed ID: 10470462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy.
    Bentley C; Peacock S; Abelson J; Burgess MM; Demers-Payette O; Longstaff H; Tripp L; Lavis JN; Wilson MG
    Health Res Policy Syst; 2019 Feb; 17(1):17. PubMed ID: 30732616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Canada's international response to HIV during times of global transition: a qualitative inquiry.
    Nixon S
    Curr HIV Res; 2011 Apr; 9(3):194-201. PubMed ID: 21457132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canada and access to medicines in developing countries: intellectual property rights first.
    Lexchin J
    Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whose feminism(s)? Overseas partner organizations' perceptions of Canada's Feminist International Assistance Policy.
    Rao S; Tiessen R
    Int J; 2020 Sep; 75(3):349-366. PubMed ID: 33149367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Value assessment of oncology drugs using a weighted criterion-based approach.
    Ezeife DA; Dionne F; Fares AF; Cusano ELR; Fazelzad R; Ng W; Husereau D; Ali F; Sit C; Stein B; Law JH; Le L; Ellis PM; Berry S; Peacock S; Mitton C; Earle CC; Chan KKW; Leighl NB
    Cancer; 2020 Apr; 126(7):1530-1540. PubMed ID: 31860138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.